NEWS
MDB Capital Collaborates with Mayo Clinic to Advance Anti-Senescence Platform
MDB Capital Holdings (NASDAQ: MDBH) has announced a collaboration with Mayo Clinic to develop a small molecule anti-senescence platform. This partnership targets research in longevity and the prevention of age-related diseases by eliminating senescent cells, which are linked to chronic low-grade inflammation and various age-related diseases, including fibrosis. Mayo Clinic's studies have demonstrated the potential of the molecule to significantly reverse fibrosis. The global market for longevity and anti-senescence therapy is projected to reach $45 billion by 2030. Both MDB's CEO, Christopher Marlett, and Mayo Clinic's Dr. Andrew J. Haak expressed enthusiasm about the collaboration's potential to advance patient care.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1050Followers
65Following
7142Visitors
Follow